<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658147</url>
  </required_header>
  <id_info>
    <org_study_id>J20121</org_study_id>
    <secondary_id>IRB00246739</secondary_id>
    <nct_id>NCT04658147</nct_id>
  </id_info>
  <brief_title>Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of neoadjuvant/adjuvant&#xD;
      Nivolumab or Nivolumab plus Relatlimab in patients with HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who complete pre-op treatment and proceed to surgery</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who obtain R0 resection</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of evaluable patients who obtain a pathologic complete response (pCR) or major pathologic response (MPR)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>ORR is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at any time during the study. CR = disappearance of all target lesions, PR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (PD) is &gt;20% increase in sum of diameters of target lesions, stable disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Number of months from the date of first treatment until disease recurrence at 12 months. Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Number of months from the date of first treatment until disease recurrence at 18 months. Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) at 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>Number of months from the date of first treatment until disease recurrence at 3 years. Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS) at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Number of months from the date of first treatment until disease recurrence at 5 years. Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A - Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Nivolumab only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Nivolumab and Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Nivolumab and Relatlimab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.</description>
    <arm_group_label>Arm A - Nivolumab</arm_group_label>
    <arm_group_label>Arm B - Nivolumab and Relatlimab</arm_group_label>
    <other_name>OPDIVO™</other_name>
    <other_name>BMS 936558</other_name>
    <other_name>MDX1106</other_name>
    <other_name>ONO-4538</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <description>Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.</description>
    <arm_group_label>Arm B - Nivolumab and Relatlimab</arm_group_label>
    <other_name>BMS-986016</other_name>
    <other_name>BMS-986016-01</other_name>
    <other_name>Anti-LAG-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Technically resectable HCC as defined by:&#xD;
&#xD;
          -  HCC may be diagnosed pathologically, or noninvasively by the American Association for&#xD;
             the Study of Liver Diseases (AASLD) criteria or the Organ Procurement and Transplant&#xD;
             Network (OPTN) Obligatory Diagnostic Criteria for Hepatocellular Carcinoma (HCC).&#xD;
&#xD;
        No extrahepatic spread, no nodal disease, and no bilateral left and right branch portal&#xD;
        vein involvement.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1 as determined by the investigator.&#xD;
&#xD;
          -  Age ≥ 18 years old on the day of consent.&#xD;
&#xD;
          -  ECOG performance status ≤1 or Karnofsky ≥80.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function defined by study-specified&#xD;
             laboratory tests prior to initial study drug.&#xD;
&#xD;
          -  Patients must have adequate liver remnant and function.&#xD;
&#xD;
          -  Antiviral therapy per local standard of care for hepatitis B.&#xD;
&#xD;
          -  LVEF assessment with documented LVEF ≥ 50% by either TTE or MUGA (TTE preferred)&#xD;
             within 6 months from first study drug administration.&#xD;
&#xD;
          -  Woman of child-bearing potential must have a negative pregnancy test.&#xD;
&#xD;
          -  Must use acceptable form of birth control while on study.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrolamellar carcinoma or mixed HCC.&#xD;
&#xD;
          -  Receiving, or previously received, any systemic chemotherapy, or investigational agent&#xD;
             for HCC.&#xD;
&#xD;
          -  Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CTLA4, or anti-Lag-3 antibodies.&#xD;
&#xD;
          -  Has a known additional malignancy that is expected to require active treatment within&#xD;
             two years, or is likely to be life-limiting in the opinion of the treating&#xD;
             investigator. Superficial bladder cancer, non-melanoma skin cancers, or low grade&#xD;
             prostate cancer not requiring therapy would not exclude participation in this trial.&#xD;
&#xD;
          -  History of HIV infection.&#xD;
&#xD;
          -  Active co-infection with HBV and HDV.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy.&#xD;
&#xD;
          -  Prior tissue or organ allograft or allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  History of any autoimmune disease requiring systemic treatment within the past 2&#xD;
             years.&#xD;
&#xD;
          -  Systemic or topical corticosteroids at immunosuppressive doses (&gt; 10 mg/day of&#xD;
             prednisone or equivalent).&#xD;
&#xD;
          -  Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year&#xD;
             prior to informed consent.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness.•&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease.&#xD;
&#xD;
          -  Significant heart disease.&#xD;
&#xD;
          -  Moderate or severe ascites.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to study treatment.&#xD;
&#xD;
          -  Are pregnant or breastfeeding.&#xD;
&#xD;
          -  WOCBP and men with female partners (WOCBP) who are not willing to use contraception.&#xD;
&#xD;
          -  Unable to have blood drawn.&#xD;
&#xD;
          -  Any other sound medical, psychiatric, and/or social reason as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Any illicit drugs or other substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Yarchoan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SKCCC Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bradley Wilt, RN</last_name>
    <phone>410-614-1816</phone>
    <email>bwilt1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trish Brothers, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Wilt, RN</last_name>
      <phone>410-614-1816</phone>
      <email>bwilt1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Trish Brothers, RN</last_name>
      <phone>410-614-3644</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relatlimab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Anti PD-1</keyword>
  <keyword>Anti - LAG-3</keyword>
  <keyword>Resectable hepatocellular Cancer</keyword>
  <keyword>Potentially resectable hepatocellular Cancer</keyword>
  <keyword>Hepatocellular Cancer (HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

